Physician profile
Mary Elizabeth Younger
NPI 1295779304
$129,952.24
in general payments reported to CMS, 2019-2025
10 companies · $28K in 2025
The $28K reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $20K · 2023: $33K · 2024: $34K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $58K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Travel and Lodging: $13K · Honoraria: $6,375 · Food and Beverage: $3,075 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,481.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,112.00 |
| Travel and Lodging | $13,116.66 |
| Honoraria | $6,375.00 |
| Food and Beverage | $3,075.02 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $68,040.49 | 2023-2025 | Joenja, Ruconest |
| Horizon Therapeutics Plc | $18,948.84 | 2021-2023 | Actimmune |
| Csl Behring | $13,575.91 | 2021-2025 | Hizentra, Privigen |
| Amgen INC. | $10,896.66 | 2024-2025 | Actimmune |
| Takeda Pharmaceuticals U.S.A., INC. | $9,938.45 | 2021-2025 | Hyqvia |
| Grifols USA, LLC | $7,493.90 | 2021-2023 | Xembify |
| Octapharma USA, INC. | $750.00 | 2021 | |
| Chiesi USA, INC. | $180.00 | 2021 | |
| Sobi, INC | $77.99 | 2025 | |
| Sumitomo Pharma America, INC. | $50.00 | 2023 | Rethymic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Elizabeth Younger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.